Lexaria FY26 Q2 net loss narrows 43.8% to US$ 3 million; revenue drops to US$ 20,000

• Lexaria posted a net loss of US$ 3 million for the six months ended Feb. 28, 2026, narrowing from US$ 5.4 million a year earlier.
• Revenue slid 94.4% to US$ 20,000 on lower license fees following expiration of Premier Anti-Aging licensing contract.
• Research and development expense fell 68.5% to US$ 1.1 million after completion of Phase 1b clinical trial GLP-1-H24-4 in December 2025.
• Cash and cash equivalents totaled about US$ 5.1 million, with net working capital of US$ 5.6 million at Feb. 28, 2026.
• Management expects current cash resources to fund operations through first quarter of fiscal 2027, while noting substantial doubt about ability to continue as going concern within one year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-000687), on April 13, 2026, and is solely responsible for the information contained therein.